Last update 27 Mar 2026
CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd.

CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd.

Subsidiary Company|1997|Hebei Sheng, China|
www.e-cspc.com

Overview

Tags

Neoplasms
Endocrinology and Metabolic Disease
Hemic and Lymphatic Diseases
siRNA
Small molecule drug
Liposomal Drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Endocrinology and Metabolic Disease4
Nervous System Diseases2
Infectious Diseases2
Hemic and Lymphatic Diseases1
Neoplasms1
Immune System Diseases1
Top 5 Drug TypeCount
siRNA5
Small molecule drug3
Herbal medicine1
Liposomal Drug1
Top 5 TargetCount
PCSK9(Proprotein convertase subtilisin kexin type 9)1
ANGPTL3(Angiopoietin like 3)1
NK1R(Neurokinin 1 receptor)1
C5(Complement C5)1
Lp(a)(lipoprotein(a))1

Related

9
Drugs associated with CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd.
Mitoxantrone Hydrochloride liposomal
Target
Top II
Mechanism
Top II inhibitors
Active Org.
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd.CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd. [+4]
Originator Org.
CSPC Pharmaceutical Group Ltd.CSPC Pharmaceutical Group Ltd.
Active Indication
Peripheral T-Cell Lymphoma [+35]
Inactive Indication
Advanced gastric carcinoma [+24]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
China
First Approval Date01 Jun 2021
Shuxuening injection
Target-
Mechanism-
Active Org.
CSPC Yinhu Pharmaceutical Co., Ltd.CSPC Yinhu Pharmaceutical Co., Ltd.
Originator Org.
CSPC Yinhu Pharmaceutical Co., Ltd.CSPC Yinhu Pharmaceutical Co., Ltd.
Active Indication
Angina Pectoris [+2]
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
China
First Approval Date16 Jul 2020
Clevidipine
Target
L-type calcium channel
Mechanism
L-type calcium channel blockers
Active Org.
Qilu Pharmaceutica Hainanco Ltd.Qilu Pharmaceutica Hainanco Ltd. [+5]
Originator Org.
The Medicines Company (Spain) SL
Active Indication
Hypertension [+2]
Inactive Indication
Aneurysm, Intracranial Berry, 1 [+6]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
United States
First Approval Date01 Aug 2008
60
Clinical Trials associated with CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd.
NCT07421297
/ Not yet recruitingPhase 3
A Phase Ⅲ Randomized, Parallel-group, Placebo-controlled Trial to Assess the Efficacy, Safety of the SYH2053 Subcutaneous Injection as Monotherapy in Participants With Primary Hypercholesterolemia (Non-familial) or Mixed Dyslipidemia
NCT07421284
/ Not yet recruitingPhase 3
A Phase Ⅲ Randomized, Parallel-group, Placebo-controlled Trial to Assess the Efficacy, Safety of the SYH2053 Subcutaneous Injection in Participants With Primary Hypercholesterolemia (Non-familial) or Mixed Dyslipidemia on a Background of Lipid-lowering Therapy
NCT07465263
/ Not yet recruitingPhase 3
A Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Clinical Trial
100 Clinical Results associated with CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd.
Login to view more data
0 Patents (Medical) associated with CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd.
Login to view more data
100 Deals associated with CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd.
Login to view more data
100 Translational Medicine associated with CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 29 Mar 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1
4
3
Phase 3
Approved
2
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free